학술논문
2019 Update of Indian National Association for Study of the Liver Consensus on Prevention, Diagnosis, and Management of Hepatocellular Carcinoma in India: The Puri II Recommendations.
Document Type
Article
Author
Kumar, Ashish; Acharya, Subrat K.; Singh, Shivaram P.; Arora, Anil; Dhiman, Radha K.; Aggarwal, Rakesh; Anand, Anil C.; Bhangui, Prashant; Chawla, Yogesh K.; Datta Gupta, Siddhartha; Dixit, Vinod K.; Duseja, Ajay; Kalra, Naveen; Kar, Premashish; Kulkarni, Suyash S.; Kumar, Rakesh; Kumar, Manoj; Madhavan, Ram; Mohan Prasad, V.G.; Mukund, Amar
Source
Subject
*HEPATOCELLULAR carcinoma
*MEDICAL care costs
*LIVER
*CHRONICALLY ill
*
*
*
Language
ISSN
0973-6883
Abstract
Hepatocellular carcinoma (HCC) is one of the major causes of morbidity, mortality, and healthcare expenditure in patients with chronic liver disease in India. The Indian National Association for Study of the Liver (INASL) had published its first guidelines on diagnosis and management of HCC (The Puri Recommendations) in 2014, and these guidelines were very well received by the healthcare community involved in diagnosis and management of HCC in India and neighboring countries. However, since 2014, many new developments have taken place in the field of HCC diagnosis and management, hence INASL endeavored to update its 2014 consensus guidelines. A new Task Force on HCC was constituted that reviewed the previous guidelines as well as the recent developments in various aspects of HCC that needed to be incorporated in the new guidelines. A 2-day round table discussion was held on 5th and 6th May 2018 at Puri, Odisha, to discuss, debate, and finalize the revised consensus statements. Each statement of the guideline was graded according to the Grading of Recommendations Assessment Development and Evaluation system with minor modifications. We present here the 2019 Update of INASL Consensus on Prevention, Diagnosis, and Management of Hepatocellular Carcinoma in India: The Puri-2 Recommendations. [ABSTRACT FROM AUTHOR]